Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has given final apprpval to Matrix Laboratories' abbreviated new drug application (ANDA) for Gabapentin capsules USP, 100 mg, 300 mg and 400 mg.
Subscribe to our email newsletter
Matrix Laboratories, a subsidiary of Mylan, claims Gabapentin capsules USP are the genereic version of Pfizer’s treatment for painful complication of shingles, Neurontin capsules.
Gabapentin capsule is an anticonvulsant. The inactive ingredients for the capsules are corn starch and talc.
The company said that it will be launching the product immediately.